<p>Bronchopulmonary Dysplasia: An Overview</p>

Abstract

Bronchopulmonary dysplasia (BPD) is the most common long-term respiratory morbidity of infants born prematurely. Historically thought to be a direct consequence of lung injury from mechanical ventilation and exposure to high concentrations of oxygen, recent evidence suggests that the BPD of today may be the result of altered lung development and altered alveolarization. In this paper, we will review historical and contemporary definitions of BPD as well as frequently used prevention and management strategies.

Bronchopulmonary dysplasia in patients of a kangaroo mother program in Popayán-Colombia. Retrospective cohort study

“…La población evaluada en su mayoría perteneció a estratos socioeconómicos bajos, la mitad de los pacientes tuvo procedencia rural, un inadecuado número de controles prenatales para la edad gestacional y un 20% no recibió maduración pulmonar adecuada; estos factores se relacionan con barreras de acceso a la atención en salud y desenlaces adversos como el compromiso nutricional materno, la prematurez o el bajo peso al nacer, factores determinantes en el desarrollo de DBP 21,22 . El uso de esteroides antenatales para la prevención del desarrollo de DBP, se encuentra descrito en la literatura por su impacto en los factores involucrados en la patogenia de la displasia porque disminuye el riesgo de patologías respiratorias y no respiratorias que conllevan elevada morbilidad y mortalidad en el periodo neonatal 23,24 .…”

Volume Guarantee Versus Pressure Limited Ventilation in Reduction of BPD (Bronchopulmonary Dysplasia) Incidence and Sequels in Preterm Infants

“…After undergoing ventilation as well as a high availability of oxygen for RDS, a subset of preterm newborns had chronic lung illness, which was being recorded in 1967. Bronchopulmonary dysplasia (BPD) that has recently been defined as the requirement for supplemental oxygen gas at either two time points: 28 days after delivery or 36 weeks after gestation (6) . In additional to oxygen reliance at 36 weeks' postmenstrual phase, the new definition considers total time of oxygen supplementing, the necessity for the positive case of pressure ventilation or nasal constant positive airway pressure (CPAP), and MV.…”

Headway and the remaining hurdles of mesenchymal stem cells therapy for bronchopulmonary dysplasia

“…Despite a considerable number (241) of in‐human clinical trials registered in ClinicalTrials.gov and the progression in neonatal medicine witnessed in the last five decades, the problem of lack of good therapeutic alternatives for bronchopulmonary dysplasia (BPD) continues to exist. Treatment strategies (Table 1) ranging from medications (antibiotics and diuretics) to steroid treatments all proved incapable of curing BPD and instead only aimed to aid the breathing of afflicted individuals 1–8 . As the occurrence of BPD correlates with prematurity and extremely low gestational age newborns (ELGANs), with approximately every 50 000 ELGANs born, the numbers that develop BPD exceeds that of 18 000 9 .…”

“…Treatment strategies (Table 1 ) ranging from medications (antibiotics and diuretics) to steroid treatments all proved incapable of curing BPD and instead only aimed to aid the breathing of afflicted individuals. 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 As the occurrence of BPD correlates with prematurity and extremely low gestational age newborns (ELGANs), with approximately every 50 000 ELGANs born, the numbers that develop BPD exceeds that of 18 000. 9 The past few decades have witnessed a plateau of about 40% in the incidence of BPD within infants of less than or equal to 28 weeks gestational age (GA).…”